Trial Profile
A Phase 1, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of Clostridium Difficile Vaccine Administered In Healthy Japanese Adults Aged 65 To 85 Years.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs PF 6425090 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions
- Sponsors Pfizer
- 05 Apr 2019 Results assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults published in the Vaccine
- 24 Apr 2018 In the day regimen, enrollment and dosing was discontinued after 3 subjects reported severe redness after the second vaccine dose.
- 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases